Cargando…
When is proton pump inhibitor use appropriate?
Proton pump inhibitor (PPI) therapy is commonly used outside of Food and Drug Administration indication for a broad range of conditions such as extra-esophageal reflux and PPI-responsive esophageal eosinophilia. While this may be appropriate in some scenarios, it has also resulted in widespread inap...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319103/ https://www.ncbi.nlm.nih.gov/pubmed/28219434 http://dx.doi.org/10.1186/s12916-017-0804-x |
_version_ | 1782509317931401216 |
---|---|
author | Yadlapati, Rena Kahrilas, Peter J. |
author_facet | Yadlapati, Rena Kahrilas, Peter J. |
author_sort | Yadlapati, Rena |
collection | PubMed |
description | Proton pump inhibitor (PPI) therapy is commonly used outside of Food and Drug Administration indication for a broad range of conditions such as extra-esophageal reflux and PPI-responsive esophageal eosinophilia. While this may be appropriate in some scenarios, it has also resulted in widespread inappropriate PPI use. At the same time, data suggesting adverse effects of long-term PPI therapy are multiplying, albeit mainly from low quality studies. The systematic review by Scarpignato et al. (BMC Med 14:179, 2016) addresses this dilemma with a comprehensive analysis of the risks and benefits of PPI use. The authors concluded that, while PPIs are highly efficacious in erosive acid-peptic disorders, efficacy is not equaled in other conditions. In some instances, they found no supportive evidence of benefit. With respect to side effects, they indicated that the questionable harms associated with PPI therapy do not outweigh the benefits afforded by appropriate PPI use. However, inappropriate PPI use results in increased healthcare costs and unnecessary exposure to potential adverse effects. Ideally, PPI therapy should be personalized, based on indication, effectiveness, patient preference, and risk assessment. Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0718-z. |
format | Online Article Text |
id | pubmed-5319103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53191032017-02-24 When is proton pump inhibitor use appropriate? Yadlapati, Rena Kahrilas, Peter J. BMC Med Commentary Proton pump inhibitor (PPI) therapy is commonly used outside of Food and Drug Administration indication for a broad range of conditions such as extra-esophageal reflux and PPI-responsive esophageal eosinophilia. While this may be appropriate in some scenarios, it has also resulted in widespread inappropriate PPI use. At the same time, data suggesting adverse effects of long-term PPI therapy are multiplying, albeit mainly from low quality studies. The systematic review by Scarpignato et al. (BMC Med 14:179, 2016) addresses this dilemma with a comprehensive analysis of the risks and benefits of PPI use. The authors concluded that, while PPIs are highly efficacious in erosive acid-peptic disorders, efficacy is not equaled in other conditions. In some instances, they found no supportive evidence of benefit. With respect to side effects, they indicated that the questionable harms associated with PPI therapy do not outweigh the benefits afforded by appropriate PPI use. However, inappropriate PPI use results in increased healthcare costs and unnecessary exposure to potential adverse effects. Ideally, PPI therapy should be personalized, based on indication, effectiveness, patient preference, and risk assessment. Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0718-z. BioMed Central 2017-02-21 /pmc/articles/PMC5319103/ /pubmed/28219434 http://dx.doi.org/10.1186/s12916-017-0804-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary Yadlapati, Rena Kahrilas, Peter J. When is proton pump inhibitor use appropriate? |
title | When is proton pump inhibitor use appropriate? |
title_full | When is proton pump inhibitor use appropriate? |
title_fullStr | When is proton pump inhibitor use appropriate? |
title_full_unstemmed | When is proton pump inhibitor use appropriate? |
title_short | When is proton pump inhibitor use appropriate? |
title_sort | when is proton pump inhibitor use appropriate? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319103/ https://www.ncbi.nlm.nih.gov/pubmed/28219434 http://dx.doi.org/10.1186/s12916-017-0804-x |
work_keys_str_mv | AT yadlapatirena whenisprotonpumpinhibitoruseappropriate AT kahrilaspeterj whenisprotonpumpinhibitoruseappropriate |